Insight

Translational Breast Cancer Research Consortium Trial 022 – Annals of Oncology

Photo of Rachel Freedman taken from www.dana-farber.org

Jul 9, 2024, 06:03

Translational Breast Cancer Research Consortium Trial 022 – Annals of Oncology

Annals of Oncology made the following post on X:

“New article in press: Neratinib and Ado-Trastuzumab-Emtansine for Pre-treated and Untreated HER2-positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium Trial 022.

Waterfall plots displaying the best RANO-BM CNS responses.”

Translational Breast Cancer Research Consortium Trial 022 - Annals of Oncology ”

Read the study.
Source: Annals of Oncology/X

Ado-Trastuzumab-Emtansine Annals of Oncology brain metastases Breast Cancer cancer clinical trials HER2-positive Neratinib OncoDaily Oncology RANO-BM translational research

Oncologist Near Me - Vivek Subbiah: Pionner of Precision Oncology

Monica Bertagnolli is ending her tenure as NIH director

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

Special Coverage